Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First Line Metastatic Colorectal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04034459
What this trial is testing

FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Who this might be right for
Metastatic Colorectal Cancer
Ludwig-Maximilians - University of Munich 109
Post-approval studies (Phase 4)UnknownNCT01023633
What this trial is testing

OPTIMOX1 in Chinese mCRC Patients

Who this might be right for
Colorectal Cancer
Nanjing Medical University 300
Testing effectiveness (Phase 2)Study completedNCT01677884
What this trial is testing

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Who this might be right for
Colorectal Neoplasms
Gustave Roussy, Cancer Campus, Grand Paris 10
Testing effectiveness (Phase 2)Study completedNCT00354978
What this trial is testing

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
M.D. Anderson Cancer Center 49
Testing effectiveness (Phase 2)Ended earlyNCT00107315
What this trial is testing

Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Roswell Park Cancer Institute 16
Large-scale testing (Phase 3)Looking for participantsNCT06997497
What this trial is testing

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Who this might be right for
Colon AdenocarcinomaRectal Adenocarcinoma
Merck Sharp & Dohme LLC 477
Testing effectiveness (Phase 2)WithdrawnNCT01270438
What this trial is testing

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Who this might be right for
Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon Cancer+5 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT05171660
What this trial is testing

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IV
Second Affiliated Hospital, Zhejiang University, School of Medicine 446
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06858969
What this trial is testing

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 130
Testing effectiveness (Phase 2)UnknownNCT03792269
What this trial is testing

Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC

Who this might be right for
Colorectal Cancer MetastaticChemotherapy EffectChemotherapeutic Toxicity
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05694936
What this trial is testing

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group 38
Large-scale testing (Phase 3)Looking for participantsNCT06642844
What this trial is testing

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Who this might be right for
Unresectable Metastatic Colorectal Cancer
University Hospital, Tours 244
Testing effectiveness (Phase 2)WithdrawnNCT02413853
What this trial is testing

Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer

Who this might be right for
Colorectal AdenocarcinomaStage IVA Colorectal CancerStage IVB Colorectal Cancer
University of Southern California
Large-scale testing (Phase 3)UnknownNCT02339116
What this trial is testing

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 654
Testing effectiveness (Phase 2)Study completedNCT00778830
What this trial is testing

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)

Who this might be right for
Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 289
Large-scale testing (Phase 3)Study completedNCT00484939
What this trial is testing

Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hoffmann-La Roche 280
Early research (Phase 1)Looking for participantsNCT07500298
What this trial is testing

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Who this might be right for
Phase 1SAR445877FOlfox6+4 more
M.D. Anderson Cancer Center 41
Large-scale testing (Phase 3)Ended earlyNCT04856787
What this trial is testing

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Who this might be right for
Metastatic Colorectal Cancer (mCRC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 62
Large-scale testing (Phase 3)WithdrawnNCT01786538
What this trial is testing

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Who this might be right for
Metastatic Colorectal Cancer
Asan Medical Center
Not applicableLooking for participantsNCT05299840
What this trial is testing

Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Oncomedics 450
Next Page